EXPERT OPINION

Explore opinions from healthcare professionals who are passionate about optimising management of patients with type 2 diabetes.

Improving Diabetes Steering Committee – Appropriate use of SGLT2i’s

The Improving Diabetes Steering Committee has developed a consensus document to provide UK prescribers with balanced and accurate information about diabetes medicines, particularly around the appropriate use of SGLT2 inhibitors.

View the consensus document

IMPROVING DIABETES STEERING COMMITTEE – SGLT2 INHIBITORS: BENEFITS BEYOND HBA1C – TRANSLATING EVIDENCE INTO PRACTICE

Cardiovascular disease (CVD), including heart failure (HF), is a leading causes of morbidity and mortality in people with type 2 diabetes (T2D). This paper examines the role of SGLT2i therapy for people with T2D who are at risk of, or who have, CVD.

View the consensus document

Early Intensification of therapy for type 2 diabetes – Practice Nurse Supplement

The importance of achieving target HbA1c in the early years. Judy Downey, Practice Nurse 2018;48(01):12-16

Achieving good glycaemic control in the early years after diagnosis of type 2 diabetes reduces the time spent in a hyperglycaemic state and thus decreases the ‘glycaemic legacy’ effect – and so can be expected to lessen or delay the occurrence of complications.

View the Practice Nurse supplement

Managing type 2 diabetes, beyond glycaemic control – Practice Nurse Supplement

An extended role for newer agents in T2D Beverley Bostock-Cox, Practice Nurse 2018;48(10):25-29

Recent studies of newer glucose-lowering therapies indicate that some may also help to protect against cardiovascular and other complications of diabetes, beyond simply lowering blood glucose levels. In this article we will consider the increasing body of evidence for an extended role for some of the agent used in the management of type 2 diabetes.

View the Practice Nurse supplement